A pilot study on reducing complexity of drug treatment while taking patients' preferences into account

A pilot study on reducing complexity of drug treatment while taking patients' preferences into account - HIOPP-6

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00025257

Enrollment

150

Registered

2021-05-17

Start date

2018-05-02

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

complexity of drug treatment

Interventions

Group 1: Verwendung einer Version des Werkzeugs, das auf die automatisierte Komplexitätsanalyse beschränkt ist Group 2: Use of a version of the tool that is restricted to the automated analysis Group

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Use of more than 5 drugs. 2) Regular use of the drugs 3) Written informed consent 4) Written informed consent of staff of family practice

Exclusion criteria

Exclusion criteria: 1) Insufficient proficiency in German 2) Cognitive and physical impairments that make it impossible to conduct the study 3) Absence or withdrawal of informed consent 4) Absence or withdrawal of informed consent of staff of family practice

Design outcomes

Primary

Measure	Time frame
Mean difference of proposed and actually implemented (i.e. perceived as helpful by patients) optimization measures in the intervention group (automated and personalized complexity analysis) compared to the control group (automated complexity analysis without standardized personalization).	—

Secondary

Measure	Time frame
- Comparison of identified complexity factors with and without automated analysis in group 3. - Comparison of type and number of complexity factors detected in groups 1, 2 and 3 - Comparison of type and number of complexity factors proposed for intervention in group 1, 2 and 3 - Comparison of type and number of optimization measures proposed and implemented - Evaluation of the relevance of automated-identifiable complexity factors for patients via key questions - Identification of non-automated-identified complexity factors via general key questions - Identification of barriers or facilitating factors in the perception of optimization measures (evaluation of the process) - Identification of factors influencing the selection and perception of optimization measures (e.g. type of optimization measure, number of total optimization measures, group)	—

Measure

Time frame

- Comparison of identified complexity factors with and without automated analysis in group 3. - Comparison of type and number of complexity factors detected in groups 1, 2 and 3 - Comparison of type and number of complexity factors proposed for intervention in group 1, 2 and 3 - Comparison of type and number of optimization measures proposed and implemented - Evaluation of the relevance of automated-identifiable complexity factors for patients via key questions - Identification of non-automated-identified complexity factors via general key questions - Identification of barriers or facilitating factors in the perception of optimization measures (evaluation of the process) - Identification of factors influencing the selection and perception of optimization measures (e.g. type of optimization measure, number of total optimization measures, group)

—

Countries

Germany

Contacts

Public ContactViktoria Wurmbach

Abteilung Klinische Pharmakologie und Pharmakoepidemiologie, Kooperationseinheit Klinische Pharmazie

viktoria.wurmbach@med.uni-heidelberg.de0049(0)6221/5636988

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 17, 2026